Sapu Nano Announces First Patient Dosed in Phase 1b Trial of Sapu003, an Intravenous Deciparticle™ Formulation of Everolimus
Sapu Nano and Oncotelic announced the first patient dosed in a Phase 1b trial of Sapu003, an intravenous formulation of everolimus for advanced mTOR-sensitive solid tumors. The open-label, dose-escalation study will evaluate safety and pharmacokinetics in two cohorts: HR+/HER2- breast cancer (combination therapy) and RCC, NETs, TSC, or HCC (monotherapy).
Key figures
- Drug Name
- Sapu003
- Phase Of Trial
- Phase 1b
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.